Leerink Partnrs Analysts Lower Earnings Estimates for Alumis

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of Alumis in a report released on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($9.55) per share for the year, down from their prior estimate of ($8.13). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. Leerink Partnrs also issued estimates for Alumis’ Q4 2024 earnings at ($1.34) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.52) EPS, FY2027 earnings at ($6.54) EPS and FY2028 earnings at ($4.04) EPS.

Other equities analysts have also issued research reports about the stock. Guggenheim initiated coverage on shares of Alumis in a research report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 target price for the company. Baird R W upgraded Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Leerink Partners assumed coverage on Alumis in a report on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Finally, Morgan Stanley assumed coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 target price for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $26.83.

Alumis Stock Performance

NASDAQ ALMS opened at $10.35 on Monday. Alumis has a 12 month low of $8.23 and a 12 month high of $13.53. The business has a 50 day simple moving average of $11.16.

Institutional Trading of Alumis

Several institutional investors have recently added to or reduced their stakes in ALMS. BNP Paribas Financial Markets purchased a new stake in shares of Alumis in the third quarter worth approximately $27,000. MetLife Investment Management LLC bought a new stake in shares of Alumis during the third quarter worth $89,000. Barclays PLC purchased a new stake in shares of Alumis during the third quarter valued at $197,000. Maven Securities LTD bought a new position in shares of Alumis in the second quarter worth about $332,000. Finally, State Street Corp purchased a new position in Alumis in the 3rd quarter worth about $866,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.